COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver

Obesity

Volumn 17, Issue 6, 2009, Pages 1150-1157

  Hsieh, Po Shiuan ^a   Jin, Jong Shiaw ^b   Chiang, Chih Fan ^a   Chan, Pei Chi ^a   Chen, Chih Hao ^a   Shih, Kuang Chung ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRUG DERIVATIVE; INSULIN; LEPTIN; MEMBRANE PROTEIN; NIMESULIDE; PROSTAGLANDIN F2 ALPHA; PTGS1 PROTEIN, RAT; PTGS2 PROTEIN, RAT; PYRAZOLE DERIVATIVE; SULFONAMIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CELL SIZE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; FATTY LIVER; GENETICS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIVER; MACROPHAGE; MALE; METABOLISM; OBESITY; PANNICULITIS; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TIME;

ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CELL SIZE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROST; DISEASE MODELS, ANIMAL; FATTY LIVER; INSULIN; INSULIN RESISTANCE; LEPTIN; LIVER; MACROPHAGES; MALE; MEMBRANE PROTEINS; OBESITY; PANNICULITIS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TIME FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 67650484314     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.674     Document Type: Article

References (40)

1. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-823.
2. Dandona P, Aljada A, Bandyopadhyay A et al. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
3. Miller C, Bartges J, Cornelius L, Norton N, Barton M. Tumor necrosis factor-α levels in adipose tissue of lean and obese cats. J Nutr 1998;128(Suppl 12):S2751-S2752.
4. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
5. Bolduc C, Larose M, Lafond N et al. Adipose tissue transcriptome by serial analysis of gene expression. Obes Res 2004;12:750-757.
6. Fain JN, Kanu A, Bahouth SW et al. Comparison of PGE2, prostacyclin and leptin release by human adipocytes versus explants of adipose tissue in primary culture. Prostaglandins Leukot Essent Fatty Acids 2002;67: 467-473.
7. Konheim YL, Wolford JK. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet 2003;113:377-381.
8. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004;109:1729-1734.
9. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372.
10. Jiang J, Torok N, Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 2008;6:1-7.
11. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004;36:165-173.
12. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA 1999;96:2327-2332.
13. Harris RB, Zhou J, Redmann SM Jr et al. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998;139:8-19.
14. Burdan F, Szumilo J, Marzec B, Klepacz R, Dudka J. Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI) WUBR rats. Toxicology 2005;216:204-223.
15. Burdan F Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats - DFU and piroxicam study. Toxicology 2005;211:12-25.
16. Yoshino T, Kimoto A, Kobayashi S et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. Arzneimittelforschung 2005;55: 394-402.
17. Hsieh PS, Tai YH, Hsieh P-S, Tai Y.-H. Aqueous extract of Monascus purpureus M9011 prevents and reverses fructose-induced hypertension in rats. J Agric Food Chem 2003;51:3945-3950.
18. Galipeau D, Arikawa E, Sekirov I, McNeill JH. Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. Hypertension 2001;38:872-876.
19. Matthews DR, Hosker JR Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-E223.
21. Cawthorn WP, Sethi JK. TNF-α and adipocyte biology. FEBS Lett 2008;582: 117-131.
22. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 1994;94:1543-1549.
23. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
24. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor a: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-1278.
25. Yan H, Kermouni A, Abdel-Hafez M et al. Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells. J Lipid Res 2003;44:424-429.
26. McAdam BF, Catella-Lawson F, Mardini lA et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96: 272-277.
27. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160: 1465-1470.
28. Lee E, Choi M-K, Youk H-J et al. 5-(4-Chlorophenyl)-1-(4- methoxyphenyl)-3-trifluoromethylpyrazole acts in a reactive oxygen species-dependent manner to suppress human lung cancer growth. J Cancer Res Clin Oncol 2006;132:223-233.
29. Huang Y, Liu J, Wang LZ, Zhang WY, Zhu XZ. Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons. Acta Pharmacol Sin 2005;26: 952-958.
30. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
31. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-2735.
32. Mohanty P, Ghanim H, Hamouda W et al. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002;75:767-772.
33. Correia ML, Rahmouni K, Correia MLG, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006;8:603-610.
34. Lee Y, Yu X, Gonzales F et al. PPARα is necessary for the lipogenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci USA 2002;99:11848-11853.
35. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-KB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-1312.
36. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
37. Kadowaki T, Yamauchi T, Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
38. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
39. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
40. Sakurai M, Takamura T, Ota T et al. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol 2007;42:312-317.